BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

CeMines Inc. Selected To Present At American Association for Cancer Research


10/19/2005 5:12:50 PM

GOLDEN, Colo., Feb. 24 /PRNewswire/ -- CeMines(TM) Inc., a life sciences company specializing in molecular research and development of minimally invasive clinical diagnostics and bioinformatics-based applications for targeted cancer therapeutics, today announced that the Company has been selected to make a poster presentation on Friday, Feb. 25, 2005, at the American Association for Cancer Research (AACR) Special Conference on Molecular Pathogenesis of Lung Cancer: "Opportunities for Translation to the Clinic."

The poster is titled: "Peptide Epitopes in Lung Cancer Diagnostics", presented by Mehis Pold, M.D. It is a result of collaborative work done by CeMines with partners at Karolinska Institutet, Sweden, National Institute for Health Development, Estonia and UCLA, USA.

"A number of diseases, including cancer, can be characterized by changes in autoantibody patterns. Our research has focused the detection of autoantibodies in lung cancer patients, using epitope microarrays," explained Dr. Toomas Neuman, CeMines' chief scientific officer. "Our poster describes our study of serum samples from lung cancer patients and control patients. We have identified autoantibody patterns that are characteristic for lung cancer and are able to discriminate between lung cancer patients and individuals with no cancer with very high accuracy and substantially lower false indications. Epitope microarrays will be used in our first blood-based cancer diagnostic product, CellCorrect(TM) Lung Cancer Diagnostic Kit. It is the Company's goal to pursue commercialization of a series of these blood-based cancer diagnostic arrays which are minimally invasive, cost-effective, cancer diagnostic tools."

The poster presentation will be made by Mehis Pold, M.D., CeMines' Director of Research, Molecular Medicine. Prior to joining CeMines in September 2004, Dr. Pold had been a researcher in the Division of Pulmonology at UCLA's David Geffen School of Medicine, where he played a leading role in two successful cancer-genomics-based studies explaining the role of the well- recognized inflammation modulator cyclooxygenase-2 (COX-2) in lung cancer.

CeMines(TM) Inc., a life sciences company specializing in molecular research, is developing minimally invasive clinical diagnostic tests and targeted therapeutics for cancer. CeMines' novel approach to understanding human cellular regulatory mechanisms resulted in the discovery of CeMines Molecular FingerPrinting(TM), a patent-pending bioinformatics process for identification and profiling of cancer cells. CeMines' headquarters is in Golden, Colorado: http://www.cemines.com/.

CeMines(TM) Inc.

CONTACT: Ronald Trahan, APR, of Ronald Trahan Associates Inc.,+1-781-762-9782, ext. 18



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES